Psychiatry research case reports最新文献_第4页

Neural reactivity to a racial trauma cue in an African American woman with alcohol use disorder and PTSD: Case report 非裔美国妇女酒精使用障碍和创伤后应激障碍对种族创伤提示的神经反应：病例报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-10-04 DOI: 10.1016/j.psycr.2025.100293

Delisa G. Brown , Amber M. Jarnecke , Tanya C. Saraiya , Elizabeth J. Santa-Ana , Kevin M. Gray , Jane J. Joseph , Sudie E. Back

{"title":"Neural reactivity to a racial trauma cue in an African American woman with alcohol use disorder and PTSD: Case report","authors":"Delisa G. Brown , Amber M. Jarnecke , Tanya C. Saraiya , Elizabeth J. Santa-Ana , Kevin M. Gray , Jane J. Joseph , Sudie E. Back","doi":"10.1016/j.psycr.2025.100293","DOIUrl":"10.1016/j.psycr.2025.100293","url":null,"abstract":"<div><div>Alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD) are common co-occurring diagnoses that disproportionately affect racial minorities and women. Black/African American women are more likely to experience racial trauma, which compounds AUD+PTSD comorbidity. Limited research has investigated the effect of racial trauma on AUD+PTSD using functional magnetic resonance imaging (fMRI). We used a novel script-driven imagery procedure during MRI for racial trauma in a 26-year-old, self-identifying Black woman enrolled in a 12-week randomized clinical trial for individuals with AUD+PTSD. During a baseline fMRI scan, the participant listened to personalized audio scripts of an index traumatic event cue (i.e., “PTSD cue”), an alcohol-related cue, a racial trauma cue, and a neutral cue. This case report describes comparisons of brain reactivity between the racial trauma and PTSD cue, and the racial trauma and alcohol cue. In this Black woman with AUD+PTSD, the racial trauma cue elicited unique activation patterns in sensorimotor and interoceptive brain regions. These patterns partially overlapped with but were distinct from activations observed during PTSD and alcohol cues. Racial trauma showed greater activation than the PTSD cue in self-referential (e.g. posterior cingulate cortex) and sensorimotor regions, and broader activation than the alcohol cue across temporal, occipital, and frontal regions. These findings suggest racial trauma may engage unique neural pathways related to emotional pain, self-referential processing, and hypervigilance. While preliminary, this case study offers insights into the neurobiological signature of racial trauma and underscores the need to include culturally specific stressors in trauma and addiction research.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100293"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pure, anxious-depressive, and panic anxiety attacks: A Freud-inspired case series 纯粹，焦虑抑郁和恐慌性焦虑发作：弗洛伊德启发的案例系列

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-10-23 DOI: 10.1016/j.psycr.2025.100297

Hisanobu Kaiya , Takeshi Otowa

{"title":"Pure, anxious-depressive, and panic anxiety attacks: A Freud-inspired case series","authors":"Hisanobu Kaiya , Takeshi Otowa","doi":"10.1016/j.psycr.2025.100297","DOIUrl":"10.1016/j.psycr.2025.100297","url":null,"abstract":"<div><div>Freud described three types of anxiety attacks: pure anxiety attacks (PAA), characterized by sudden affective surges without ideation or somatic symptoms; anxious-depressive attacks (ADA), involving ruminative and depressive thoughts; and panic attacks (PA), dominated by autonomic arousal. Although PA has been extensively documented, PAA and ADA have received limited clinical attention.</div><div>In this retrospective case series, we reviewed outpatient clinic charts and descriptively classified recorded anxiety episodes by their predominant features, which enabled us to identify attacks lacking prominent physical symptoms. Two Japanese outpatients illustrate how these subtypes can manifest and shift within the same individual. Case A showed a temporal progression from PA to PAA and then ADA, each phase marked by distinct features. Case B initially presented ADA, followed by episodes of PA and PAA, sometimes alternating rapidly within a single episode.</div><div>These observations suggest a shared psychodynamic origin expressed through somatic, cognitive, or affective channels depending on individual and situational factors. Distinguishing PAA and ADA from PA is clinically significant, as these subtypes lack the somatic arousal that typically guides diagnosis and may show different responses to psychological versus pharmacological strategies. Our findings highlight less recognized non-somatic variants that might otherwise be overlooked in clinical practice and point toward more tailored therapeutic approaches.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100297"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145415596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Apathy in a young woman with Langerhans cell histiocytosis and hypopituitarism: a case report 冷漠的年轻女性与朗格汉斯细胞组织细胞增多症和垂体功能减退：1例报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-08-07 DOI: 10.1016/j.psycr.2025.100281

Greta Poglia, Javier Bartolomei, Marco De Pieri

{"title":"Apathy in a young woman with Langerhans cell histiocytosis and hypopituitarism: a case report","authors":"Greta Poglia, Javier Bartolomei, Marco De Pieri","doi":"10.1016/j.psycr.2025.100281","DOIUrl":"10.1016/j.psycr.2025.100281","url":null,"abstract":"<div><div>This is the case of a 24-year-old woman referred to our outpatient psychiatry clinic for depression-like symptoms in the context of multiple hormonal deficits and a lesion in hypothalamus and pituitary gland. A prior diagnostic workup had identified multisystem Langerhans cell histiocytosis (LCH) with neurologic and neuroendocrine involvement. The patient was treated with hormonal replacement, corticosteroids, chemotherapy, and antidepressant medication, however, the neuropsychiatric syndrome persisted and appeared exacerbated by challenging family dynamics. Apathy was the predominant clinical feature, pointing to a distinct phenotype that is differentiable from depression. Mild improvement was noted after initiation of therapy with dexmethylphenidate, and consideration was given to oxytocin treatment, although the latter was not pursued owing to the lack of an established protocol. This case illustrates a striking neuropsychiatric phenotype of treatment-resistant apathy occurring in the setting of neuro-LCH with localized hypothalamic-pituitary lesion and multi-endocrine deficiency. The apathy syndrome was refractory to treatments targeting LCH, hormone replacement, and antidepressants, highlighting the need for a tailored approach. The potential role of psychostimulants and oxytocin replacement as therapeutic avenues in apathic patients warrants further research.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100281"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction notice to “Assessing the use of nirmatrelvir/ritonavir and considerations regarding its drug interactions in COVID-19 positive patients at an adult inpatient state psychiatric facility” [Psychiatry Research Case Reports Volume 2, Issue 2, December 2023, 100159] 对“评估州精神病院成人住院COVID-19阳性患者使用尼马特瑞韦/利托那韦及其药物相互作用的考虑”的撤回通知[精神病学研究病例报告第2卷第2期2023年12月，100159]

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-08-08 DOI: 10.1016/j.psycr.2025.100276

Carolyn O'Donnell , Tammie Lee Demler

引用次数: 0

Erratum regarding missing Statements in previously published articles 关于先前发表的文章中缺失陈述的勘误

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-11-01 DOI: 10.1016/j.psycr.2025.100296

引用次数: 0

Retraction notice to “Psychiatric comorbidities and treatment of individuals with a sex chromosome trisomy: A case series” [Psychiatry Research Case Reports 1(2022) 100002] “性染色体三体个体的精神疾病共病和治疗：一个病例系列”的撤回通知[精神病学研究病例报告1(2022)100002]

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-06-24 DOI: 10.1016/j.psycr.2025.100265

Christopher Ferry , Victoria Soal , Rama Rao Gogineni , Alicia A. Barnes

引用次数: 0

Olanzapine-induced ankle edema: A case report on a rare adverse effect 奥氮平引起的踝关节水肿：一例罕见的不良反应报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-09-18 DOI: 10.1016/j.psycr.2025.100291

Sabina Dahal , Rishi Ram Banjade , Pramod Kumar Kafle

{"title":"Olanzapine-induced ankle edema: A case report on a rare adverse effect","authors":"Sabina Dahal , Rishi Ram Banjade , Pramod Kumar Kafle","doi":"10.1016/j.psycr.2025.100291","DOIUrl":"10.1016/j.psycr.2025.100291","url":null,"abstract":"<div><div>Olanzapine, a second-generation antipsychotic, is widely used for the treatment of schizophrenia and mood disorders but is associated with various side effects, including rare cases of peripheral edema. We report a case of a 48-year-old female with bipolar II disorder who developed bilateral pitting ankle edema 10 days after initiating olanzapine therapy. Clinical examination and investigations ruled out cardiac, renal, hepatic, and endocrine causes. The edema resolved completely within two weeks of discontinuing olanzapine and switching to amisulpride. Although peripheral edema is an uncommon adverse effect, it may mimic serious medical conditions, leading to unnecessary investigations. Several mechanisms have been proposed, including α1-adrenergic and 5-HT2 receptor blockade, contributing to vasodilation and fluid retention. This case highlights the need for clinicians to be aware of this potential reaction, allowing for timely identification and appropriate management. Reporting such cases contributes to post-marketing surveillance and supports safer, more informed use of antipsychotic medications like olanzapine.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100291"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Positive response to adjunctive KarXT (xanomeline/trospium) in treatment-resistant Schizophrenia: A case report 辅助KarXT （xanomeline/trospium）治疗难治性精神分裂症的阳性反应1例报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-07-25 DOI: 10.1016/j.psycr.2025.100280

Cade Church , Jesse Zeng , Laura Warning , Sheevaam Patel , Tessa Manning

{"title":"Positive response to adjunctive KarXT (xanomeline/trospium) in treatment-resistant Schizophrenia: A case report","authors":"Cade Church , Jesse Zeng , Laura Warning , Sheevaam Patel , Tessa Manning","doi":"10.1016/j.psycr.2025.100280","DOIUrl":"10.1016/j.psycr.2025.100280","url":null,"abstract":"<div><div>KarXT (xanomeline-trospium) is a novel, FDA-approved antipsychotic that targets muscarinic receptors rather than dopamine for use in patients with schizophrenia. Initial studies aimed at the approval of the drug showed a decrease in Positive and Negative Symptom Scale (PANSS) scores compared to placebo among patients who met the inclusion criteria for those studies. The present case report describes the use of KarXT in a 34-year-old male with schizoaffective disorder, depressed subtype, and opioid use disorder who would have been excluded from KarXT clinical trials due to extensive prior hospitalizations, multiple recently failed antipsychotic trials, and concurrent psychiatric polypharmacy. KarXT was discussed with the patient after failing to see improvement with multiple other antipsychotic medications, including clozapine, in the inpatient setting. He agreed to start KarXT in addition to the intramuscular paliperidone palmitate, mirtazapine, lorazepam, and trazodone he was already receiving. The patient’s baseline PANSS score was determined to be 86 just prior to his first dose of KarXT. By day 4, his PANSS score decreased to 46, representing a 47 % decrease. At 5 weeks, the patient was reevaluated via phone and determined to have a PANSS score of 52. These findings are an encouraging example of a patient with comorbid psychiatric diagnoses and concurrent medication regimens receiving benefit from KarXT. This case illustrates the potential utility of KarXT in a complex patient population typically excluded from trials, suggesting broader clinical applicability.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100280"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144810581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation of accelerated transcranial magnetic stimulation treatment for an individual with treatment-resistant depression: A case report 实施加速经颅磁刺激治疗难治性抑郁症：1例报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-09-07 DOI: 10.1016/j.psycr.2025.100288

Hammad Khan , Lelanie Ayala , Carol Parise

{"title":"Implementation of accelerated transcranial magnetic stimulation treatment for an individual with treatment-resistant depression: A case report","authors":"Hammad Khan , Lelanie Ayala , Carol Parise","doi":"10.1016/j.psycr.2025.100288","DOIUrl":"10.1016/j.psycr.2025.100288","url":null,"abstract":"<div><div>Major depressive disorder (MDD) is one of the most common mental disorders in the United States. Transcranial magnetic stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of major depression. However, the frequency and duration of the treatment schedule make compliance difficult for many patients. Accelerated theta-burst transcranial magnetic stimulation (TBS-rTMS), which involves multiple sessions of TMS in a single day, has shown promise for improved clinical outcomes despite a shorter treatment duration. We present a case of a 24-year-old woman with MDD with treatment-resistant depression (TRD) who was treated with accelerated TBS-rTMS at an inpatient psychiatric facility. The patient underwent 46 treatments of TBS-TMS per day over 5 days at 110 % of motor threshold in addition to group and 1:1 therapy and medications. The patient showed improvement on the Montgomery-Åsberg Depression Rating Scale (MADRS), Patient Health Questionnaire-9 (PHQ-9), Becks Depression Inventory (BDI), and General Anxiety Disorder-7 (GAD-7) over the 5-day course of treatment. One year later, PHQ-9, BDI, and GAD-7 scores were sustained. This case suggests that TBS-rTMS be considered for cases of MDD with TRD that do not respond to other forms of therapy.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100288"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145048758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clozapine treatment in chronic lymphocytic leukaemia and pancytopenia 氯氮平治疗慢性淋巴细胞白血病和全血细胞减少症

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-11-13 DOI: 10.1016/j.psycr.2025.100299

Daniel Morgan , Gurvir Singh Rai , Danilo Arnone

{"title":"Clozapine treatment in chronic lymphocytic leukaemia and pancytopenia","authors":"Daniel Morgan , Gurvir Singh Rai , Danilo Arnone","doi":"10.1016/j.psycr.2025.100299","DOIUrl":"10.1016/j.psycr.2025.100299","url":null,"abstract":"<div><div>There is a paucity of literature regarding clozapine initiation in patients with haematologic malignancies. We present the case of a patient with chronic lymphocytic leukaemia (CLL) and schizoaffective disorder whose clozapine was discontinued and restarted. A woman in her 60s presented to the emergency department with hypotension and symptomatic pancytopenia. Clozapine was discontinued due to the risk of neutropenia during her admission to the haematology service. Bone marrow aspiration revealed that the pancytopenia was due to CLL clonal invasion, and the decision was made to restart clozapine. The subsequent development of hospital-acquired pneumonia led to clozapine discontinuation. An evaluation of the harms and benefits of clozapine re-initiation is discussed considering the possible additive effects of clozapine and CLL on degrading immune function, the risk of opportunistic infections, and the cytotoxic effects of CLL treatment. In medicated patients with stable psychopathology the introduction of clozapine after completion of CCL treatment can help minimise the risk of physical complications. Earlier introduction of clozapine may be justified in symptomatic patients with close monitoring. Informed decisions should be guided by patients’ preferences after judicious evaluation of risks and benefits. Haematology-psychiatry collaboration is essential to best manage cases with complex, comorbid psychiatric and haematological conditions.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100299"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0